Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Short Interest Up 2,250.0% in April

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) was the target of a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 9,400 shares, an increase of 2,250.0% from the March 31st total of 400 shares. Based on an average daily volume of 9,000 shares, the short-interest ratio is presently 1.0 days.

Santen Pharmaceutical Price Performance

Shares of SNPHY opened at $9.81 on Friday. Santen Pharmaceutical has a 12-month low of $8.65 and a 12-month high of $13.00. The firm has a fifty day moving average price of $9.57 and a 200-day moving average price of $10.26.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension.